BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38099401)

  • 1. Update on the current and future use of CAR-T to treat multiple myeloma.
    Gahvari Z; Brunner M; Schmidt T; Callander NS
    Eur J Haematol; 2024 Apr; 112(4):493-503. PubMed ID: 38099401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma.
    Miller K; Hashmi H; Rajeeve S
    Front Oncol; 2024; 14():1398902. PubMed ID: 38800372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood.
    Lee WH; Graham CE; Wiggin HR; Nolan HK; Graham KJ; Korell F; Leick MB; Barselau AL; Emmanuel-Alejandro E; Trailor MA; Gildea JM; Preffer F; Frigault MJ; Maus MV; Gallagher KME
    Cytometry B Clin Cytom; 2024 May; 106(3):162-170. PubMed ID: 38418432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
    Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
    Front Immunol; 2022; 13():991092. PubMed ID: 36119032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
    Ghanem B; Shi L
    BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
    Rejeski K; Hansen DK; Bansal R; Sesques P; Ailawadhi S; Logue JM; Bräunlein E; Cordas Dos Santos DM; Freeman CL; Alsina M; Theurich S; Wang Y; Krackhardt AM; Locke FL; Bachy E; Jain MD; Lin Y; Subklewe M
    J Hematol Oncol; 2023 Jul; 16(1):88. PubMed ID: 37525244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM.
    Jurgens E; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):277-284. PubMed ID: 38331676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
    Anderson LD
    Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
    Fang J; Zhou F
    Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
    Fischer L; Grieb N; Platzbecker U; Vucinic V; Merz M
    Eur J Haematol; 2024 Jan; 112(1):19-27. PubMed ID: 37547971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
    Zhang M; Wei G; Zhou L; Zhou J; Chen S; Zhang W; Wang D; Luo X; Cui J; Huang S; Fu S; Zhou X; Tang Y; Ding X; Kuang J; He XP; Hu Y; Huang H
    Lancet Haematol; 2023 Feb; 10(2):e107-e116. PubMed ID: 36725117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current progress of CAR-T-cell therapy for patients with multiple myeloma.
    Nakashima T; Kagoya Y
    Int J Hematol; 2024 May; ():. PubMed ID: 38777913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
    Parikh RH; Lonial S
    CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovation in BCMA CAR-T therapy: Building beyond the Model T.
    Banerjee R; Lee SS; Cowan AJ
    Front Oncol; 2022; 12():1070353. PubMed ID: 36505779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact.
    Hosoya H; Rodriguez-Otero P; Sidana S; Borrello IM
    Am Soc Clin Oncol Educ Book; 2023 Jun; 43():e389860. PubMed ID: 37290016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
    Xia J; Li H; Yan Z; Zhou D; Wang Y; Qi Y; Cao J; Li D; Cheng H; Sang W; Zhu F; Sun H; Chen W; Qi K; Yan D; Qiu T; Qiao J; Yao R; Liu Y; Wang X; Zhang Y; Peng S; Huang CH; Zheng J; Li Z; Chang AH; Xu K
    J Clin Oncol; 2023 May; 41(14):2583-2593. PubMed ID: 36881785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.